Summary:
In patients with diabetic macular edema (DME),intravitreal aflibercept combined with dexamethasone phosphate significantly improved short-term structural and functional outcomes
compared to intravitreal aflibercept alone, though it was associated with steroid-related adverse effects such as increased intraocular pressure.
| PICO | Description |
|---|---|
| Population | Adults with diabetic macular edema (DME) confirmed by optical coherence tomography and clinical evaluation. |
| Intervention | Intravitreal aflibercept administered in combination with dexamethasone sodium phosphate. |
| Comparison | Intravitreal aflibercept monotherapy alone. |
| Outcome | The combination treatment led to significant improvements in retinal thickness and visual acuity over the short term. However, it was associated with steroid-related adverse effects, including increased intraocular pressure, requiring monitoring. |
Source: Valesca Castro Neri, et al. “Intravitreal aflibercept alone versus combination with dexamethasone phosphate for diabetic macular edema: A randomized phase-2 clinical trial.” Read article here: Read article here.
